Compare WB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WB | IDYA |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | WB | IDYA |
|---|---|---|
| Price | $9.99 | $30.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $14.00 | ★ $49.85 |
| AVG Volume (30 Days) | ★ 1.0M | 800.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 16.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.53 | N/A |
| Revenue Next Year | $2.38 | $97.58 |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.10 | $13.45 |
| 52 Week High | $12.96 | $39.28 |
| Indicator | WB | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 38.70 |
| Support Level | $9.70 | $29.47 |
| Resistance Level | $10.37 | $33.63 |
| Average True Range (ATR) | 0.30 | 1.60 |
| MACD | -0.06 | -0.27 |
| Stochastic Oscillator | 20.80 | 27.58 |
Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.